Long COVID Treatment Trial

09/15/2026

🎙️Julia Moore Vogel joins “A Friend for the Long Haul” podcast!

Beth, host of “A Friend for the Long Haul”, welcomed Julia Moore Vogel, Long COVID patient and LoCITT-T co-PI at Moore Vogel Lab at Scripps Research, and Dr. Wes Ely, physician-scientist at Vanderbilt and PI on REVERSE-LC trial, on "A Friend for the Long Haul" podcast to dig into Long COVID clinical trials and the process of finding the right doctor. Keep listening to hear about Beth and Julia’s shared joy of crafting, too!

🎧 Give it a listen!
https://creators.spotify.com/pod/profile/a-friend-for-the-long-hau8/episodes/Long-COVID-Clinical-Trials--Tirzepatide--Finding-the-Right-Doctor-Dr--Wes-Ely--Dr--Julia-Moore-Vogel-e3o9rd7

09/01/2026

Exciting news: Julia Moore Vogel, Assistant Professor & Sr. Program Director at Moore Vogel Lab at Scripps Research, is making headlines in Smithsonian magazine. The featured article is a well-earned spotlight on her meaningful contributions to the Long COVID community.

“Having the capability to help the community, I feel a moral obligation to use my skills for that purpose, because I feel like there’s reason for hope. And I want other people to know that–to feel that hope.”

Read the full article here: https://www.smithsonianmag.com/innovation/many-americans-covid-still-chronic-disabling-disease-scientists-working-tirelessly-bring-them-relief-180989290/

06/26/2026

A new study, highlighted in Bloomberg Law, validates that Long COVID is far more widespread than medical records reflect. For too many people with Long COVID, one of the hardest parts of being sick is being invisible to the systems that are meant to help. Without an accurate diagnosis, patients can’t access the care they need or secure the coverage they deserve.

That's why Long COVID research is so important. Research can advance science and it can give patients the documentation they need to get the care and support they deserve.

Read the full Bloomberg Law article, including insights from Julia Moore Vogel, Long COVID patient and LoCITT-T study co-PI at Scripps Research. 👉 https://news.bloomberglaw.com/health-law-and-business/long-covid-underdiagnosis-poses-broader-care-coverage-hurdles

06/24/2026

New paper by Julia Moore Vogel and colleagues in JACC: Advances and the findings are important for the Long COVID community.

This study looked at how COVID-19 affects cardiopulmonary function long term, as a digital health substudy of the nationwide Researching COVID-19 to Enhance Recovery (RECOVER) Adult Cohort Study. Using wearable devices data and quarterly surveys, the study looked at heart and lung health in 1,475 people at about 21 months after COVID infection. About 1 in 3 had symptoms that met RECOVER’s threshold for a high Long COVID Research Index score and showed measurable differences in health: lower heart rate variability, elevated resting heart rates, lower average step counts, and reduced active minutes.

Two subgroups of people were also identified to have abnormal heart health measurements and reported a low quality of life.

Long COVID is associated with worse heart and lung function. These findings raise an important question: could Long COVID be a new risk factor for things like heart attacks down the road? More research is needed and this study helps lay the groundwork.

Read the full paper here 👉 https://www.sciencedirect.com/science/article/pii/S2772963X26003443

06/05/2026

A note of thanks, and some helpful context, for our LoCITT-T participants.

Wondering what it means to be in the placebo group? LoCITT-T co-PI Julia Moore Vogel explains how placebo data works and why every participant, in every arm of the study, is contributing to meaningful Long COVID research.

To all of our LoCITT-T participants: your time and your willingness to take part mean so much. Thank you.

▶️ Watch Julia's message: https://bit.ly/lctplacebo
A transcript is also available directly on YouTube: open the video, click "...more" beneath the video title to expand the description, then click "Show transcript." The transcript panel will then appear to the side.

📃Read the transcript: https://bit.ly/lctplacebotranscript

03/19/2026

Did you know? GLP‑1 medications like Zepbound don’t affect everyone the same way. Clinical data shows that about 10% of people don’t see meaningful metabolic changes, which highlights how much results can vary. A recent New York Times article offers helpful insight into these differences. Read the article in link below.

Drugs like Wegovy and Zepbound have been hailed as miracle treatments. But one in 10 people are what scientists call “non-responders.”

03/15/2026

March is Long COVID Awareness Month. On March 15, Long COVID Awareness Day, we honor everyone living with Long COVID and the challenge they face every day.

Thank you to everyone participating in and supporting our studies including the Long COVID Treatment Trial-Tirzepatide (LoCITT‑T). Your experiences are helping move Long COVID research forward.

Your efforts enable meaningful change. Learn more about our Long COVID research at longcovid.scripps.edu.

02/23/2026

Nutrition and GLP-1s - Dietitian Janna Neitzel, MS, RD, CDN shared ways to help support your nutritional needs while chronically ill, with a special attention on the impact of taking tirzepatide. She covered different dietary options, how much protein to aim for, tips for staying hydrated, and ways to manage common symptoms – and wrapped up by answering questions from the audience. Feel free to take what’s helpful and leave the rest.

Watch the recording, slides and top Q&A questions at https://longcovid.scripps.edu/locitt-t/ -webinar

This webinar is for educational purposes only and not intended to provide medical advice. For questions related to LoCITT-T, please contact the study team.